1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
AlzeCure Pharma AB

AlzeCure Pharma AB

6.10
SEK
-0.20
(-3.17%)
0.25EPS
14.73P/E
412.80MMarket Cap
Nov 11Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.8
Basic EPS, GAAP
-0.44
-1.16
-0.98
-1.38
-1.57
-0.9
-0.46
-0.39
-0.43
0.25
Free Cash Flow per Basic Share
-0.35
-1.18
-1
-1.36
-1.42
-1.59
0.04
-0.38
-0.31
-0.43
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1
4.51
3.52
2.14
0.64
0.9
0.29
0.25
0.26
0.82
Tangible Book Value per Share
1
4.51
3.52
2.14
0.64
0.9
0.29
0.25
0.26
0.82
Basic Weighted Avg Shares
25
31
52
52
50
63
82
90
111
122
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
97
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
31.28
Depreciation Expense
- -
- -
- -
- -
1
1
- -
1
1
1
Net Income, GAAP
-11
-36
-51
-71
-78
-56
-37
-35
-48
31
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
31.56
Working Capital
52
233
180
109
32
17
22
24
31
90
LT Debt
- -
- -
- -
- -
- -
- -
5
4
3
2
Total Equity
52
233
182
111
33
60
24
26
33
91
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-25.25
-24.5
-48.75
-108.23
-120.35
-88.22
-141.83
-161.56
62.85

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
127
127
111
Market Capitalization
- -
- -
413

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55
37
119
Cash, Cash Equivalents & STI
50
33
13
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
27
29
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.31%
26.27%
Free Cash Flow
- -
-256.8%
0.7%
Net Income, GAAP
- -
-4.54%
34.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
97
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.11
-0.08
-0.1
-0.39
2025
-0.1
-0.11
-0.08
-0.14
-0.43
2026
-0.17
0.72
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Martin Jönsson
Full Time Employees
10
Sector
Health technology
Industry
Biotechnology
Address
Hälsovägen 7 Huddinge AB Sweden 141 57
IPO Date
Nov 28, 2018
Website
alzecurepharma.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
AlzeCure Pharma AB (publ) (ALZCUR.ST) is a Sweden-based pharmaceutical company founded in 2016 and headquartered in Huddinge that focuses on developing innovative small-molecule drug candidates for central nervous system disorders, primarily Alzheimer's disease and severe pain conditions; its lead platforms include NeuroRestore for symptomatic cognitive treatments, Alzstatin for disease-modifying Alzheimer's therapies, and Painless for non-opioid pain relief. Core products encompass NeuroRestore ACD856, a positive allosteric modulator of Trk receptors in Phase II clinical development targeting Alzheimer's disease, cognitive dysfunction from Parkinson's disease, traumatic brain injury, sleep disorders and depression; NeuroRestore ACD857 in research for Alzheimer's; Alzstatin ACD680, a gamma-secretase modulator in preclinical stage to reduce amyloid-beta-42 plaques; Painless ACD440, a TRPV1 antagonist gel that completed Phase IIa with positive efficacy in neuropathic pain and received U.S. FDA Orphan Drug Designation for erythromelalgia in July 2025; and Painless ACD137 (TrkA-NAM), a preclinical candidate demonstrating analgesic and anti-inflammatory effects in osteoarthritis pain models. The company operates primarily in Sweden with a diversified pipeline addressing unmet needs in neurodegenerative diseases and chronic pain for patient populations including those unresponsive to current therapies. Recent developments include a EUR 2.5 million grant from the European Innovation Council in February 2025 to support Phase IIa trials of ACD856, including higher dosing evaluations; a rights issue in July 2025 oversubscribed by 212% raising SEK 58.5 million; Orphan Drug Designation for ACD440 in erythromelalgia with positive FDA guidance for Phase IIb/III; new preclinical data for ACD137 presented at NeuPSIG 2025; appointment of Cecilia Wadell as Head of Development in August 2025; and a December 2025 payment receipt for the EIC grant.